These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 25190600)

  • 61. Modulation of intestinal microbiota, control of nitrogen products and inflammation by pre/probiotics in chronic kidney disease: a systematic review.
    Lopes RCSO; Balbino KP; Jorge MP; Ribeiro AQ; Martino HSD; Alfenas RCG
    Nutr Hosp; 2018 Apr; 35(3):722-730. PubMed ID: 29974784
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The gastrointestinal microbiome - functional interference between stomach and intestine.
    Lopetuso LR; Scaldaferri F; Franceschi F; Gasbarrini A
    Best Pract Res Clin Gastroenterol; 2014 Dec; 28(6):995-1002. PubMed ID: 25439066
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Brain-gut-microbiota axis in Parkinson's disease.
    Mulak A; Bonaz B
    World J Gastroenterol; 2015 Oct; 21(37):10609-20. PubMed ID: 26457021
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease.
    Huang Y; Xin W; Xiong J; Yao M; Zhang B; Zhao J
    Front Pharmacol; 2022; 13():837500. PubMed ID: 35370631
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Uremic Toxin-Producing Gut Microbiota in Rats with Chronic Kidney Disease.
    Kikuchi M; Ueno M; Itoh Y; Suda W; Hattori M
    Nephron; 2017; 135(1):51-60. PubMed ID: 27701177
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Gut microbiota and inflammation in chronic kidney disease patients.
    Mafra D; Fouque D
    Clin Kidney J; 2015 Jun; 8(3):332-4. PubMed ID: 26034597
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
    Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
    World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prebiotic effects: metabolic and health benefits.
    Roberfroid M; Gibson GR; Hoyles L; McCartney AL; Rastall R; Rowland I; Wolvers D; Watzl B; Szajewska H; Stahl B; Guarner F; Respondek F; Whelan K; Coxam V; Davicco MJ; Léotoing L; Wittrant Y; Delzenne NM; Cani PD; Neyrinck AM; Meheust A
    Br J Nutr; 2010 Aug; 104 Suppl 2():S1-63. PubMed ID: 20920376
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The gut microbiome, diet, and links to cardiometabolic and chronic disorders.
    Aron-Wisnewsky J; Clément K
    Nat Rev Nephrol; 2016 Mar; 12(3):169-81. PubMed ID: 26616538
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Oral iron supplementation in patients with chronic kidney disease: Can it be harmful to the gut microbiota?
    Ribeiro M; Fonseca L; Anjos JS; Capo-Chichi JCC; Borges NA; Burrowes J; Mafra D
    Nutr Clin Pract; 2022 Feb; 37(1):81-93. PubMed ID: 33979013
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Interactions between the monogastric animal gut microbiota and the intestinal immune function--a review].
    Yang L; Bian G; Zhu W
    Wei Sheng Wu Xue Bao; 2014 May; 54(5):480-6. PubMed ID: 25199246
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Gut as a Source of Inflammation in Chronic Kidney Disease.
    Lau WL; Kalantar-Zadeh K; Vaziri ND
    Nephron; 2015; 130(2):92-8. PubMed ID: 25967288
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD.
    Szeto CC; McIntyre CW; Li PK
    J Am Soc Nephrol; 2018 Jun; 29(6):1601-1608. PubMed ID: 29666156
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change.
    Liu Y; Li J; Yu J; Wang Y; Lu J; Shang EX; Zhu Z; Guo J; Duan J
    J Pharm Biomed Anal; 2018 Feb; 149():425-435. PubMed ID: 29169110
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products.
    Jaworska K; Huc T; Gawrys M; Onyszkiewicz M; Samborowska E; Ufnal M
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394384
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Patients with chronic kidney disease have abnormal upper gastro-intestinal tract digestive function: A study of uremic enteropathy.
    Grant CJ; Harrison LE; Hoad CL; Marciani L; Gowland PA; McIntyre CW
    J Gastroenterol Hepatol; 2017 Feb; 32(2):372-377. PubMed ID: 27222079
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression.
    Mosterd CM; Kanbay M; van den Born BJH; van Raalte DH; Rampanelli E
    Best Pract Res Clin Endocrinol Metab; 2021 May; 35(3):101484. PubMed ID: 33546983
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intestinal homeostasis in the gut-lung-kidney axis: a prospective therapeutic target in immune-related chronic kidney diseases.
    Liu X; Wang X; Zhang P; Fang Y; Liu Y; Ding Y; Zhang W
    Front Immunol; 2023; 14():1266792. PubMed ID: 38022571
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intestinal microbiota in inflammation and insulin resistance: relevance to humans.
    De Bandt JP; Waligora-Dupriet AJ; Butel MJ
    Curr Opin Clin Nutr Metab Care; 2011 Jul; 14(4):334-40. PubMed ID: 21587065
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Alteration of the Intestinal Environment by Lubiprostone Is Associated with Amelioration of Adenine-Induced CKD.
    Mishima E; Fukuda S; Shima H; Hirayama A; Akiyama Y; Takeuchi Y; Fukuda NN; Suzuki T; Suzuki C; Yuri A; Kikuchi K; Tomioka Y; Ito S; Soga T; Abe T
    J Am Soc Nephrol; 2015 Aug; 26(8):1787-94. PubMed ID: 25525179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.